dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gavilá Gregori, Joaquín |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.contributor.author | Pascual, Tomás |
dc.contributor.author | Pérez García, José |
dc.contributor.author | Gonzàlez, Xavier |
dc.contributor.author | Canes, Jordi |
dc.date.accessioned | 2019-02-22T11:59:06Z |
dc.date.available | 2019-02-22T11:59:06Z |
dc.date.issued | 2019-01-09 |
dc.identifier.citation | Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, et al. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. BMC Med. 2019;17(1):8. |
dc.identifier.issn | 1741-7015 |
dc.identifier.uri | https://hdl.handle.net/11351/3808 |
dc.description | Càncer de mama; HER2; Neoadjuvant |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | BMC Medicine;17(1) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer |
dc.subject | Càncer - Quimioteràpia - Complicacions |
dc.subject | Assaigs clínics |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neoadjuvant Therapy |
dc.subject.mesh | /adverse effects |
dc.subject.mesh | Clinical Trial |
dc.title | Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12916-018-1233-1 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | tratamiento neoadyuvante |
dc.subject.decs | /efectos adversos |
dc.subject.decs | ensayo clínico |
dc.relation.publishversion | https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1233-1 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gavilá J] Fundación Instituto Valenciano de Oncología, Valencia, Spain. [Oliveira M] Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Pascual T] August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Hospital Clínic, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Perez-Garcia J] Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Instituto Oncológico Baselga, Hospital Quirón, Barcelona, Spain. [Gonzàlez X] SOLTI Breast Cancer Research Group, Barcelona, Spain. Institut Oncològic Rosell, Hospital General Catalunya, Barcelona, Spain. [Canes J] SOLTI Breast Cancer Research Group, Barcelona, Spain. |
dc.identifier.pmid | 30621698 |
dc.identifier.wos | WOS:000455212100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |